Quick Answer
Revolution Medicines, Inc. reported Cash and Equivalents of $383.75 million for fiscal year 2025.
Revolution Medicines, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $383.75M | -29.3% |
| 2024 | $543.06M | -22.0% |
| 2023 | $696.15M | +331.3% |
| 2022 | $161.41M | +48.8% |
| 2021 | $108.50M | +4.1% |
| 2020 | $104.27M | +525.9% |
| 2019 | $16.66M | -76.1% |
| 2018 | $69.59M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $217.44M | +8.0% | -46.0% |
| June 30, 2025 | $402.44M | +46.0% | +20.7% |
| March 31, 2025 | $333.55M | +15.6% | -38.6% |
| December 31, 2024 | $543.06M | -22.0% | +169.8% |
| September 30, 2024 | $201.26M | -43.8% | -27.0% |
| June 30, 2024 | $275.71M | -27.5% | -4.4% |
| March 31, 2024 | $288.43M | -32.5% | -58.6% |
| December 31, 2023 | $696.15M | +331.3% | +94.2% |
- Revolution Medicines, Inc. showed a decrease of -29.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Revolution Medicines, Inc.’s cash and equivalents has grown by 451.5% (from $69.59 million to $383.75 million).
- The most recent figure is from Revolution Medicines, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: